Novo Nordisk + OpenAI
Novo Nordisk announced a partnership with OpenAI to apply artificial intelligence across drug discovery, manufacturing and commercial operations, aiming to speed analysis of complex datasets. The deal is part of a wider Danish push to build AI infrastructure for healthcare, including connections to national supercomputing resources. (reuters.com) (cnbc.com) (euronews.com)
Novo Nordisk said on April 14 it is partnering with OpenAI to use artificial intelligence across drug discovery, manufacturing and commercial work. (reuters.com) The Danish drugmaker said OpenAI’s tools will help analyze large datasets, identify drug candidates and improve efficiency in supply chains, distribution and other corporate operations. Novo did not disclose financial terms. (cnbc.com) Novo said the rollout will cover its global business and include training for employees, with the partnership structured around data governance and human oversight. (biospace.com) Drug discovery starts with pattern-finding in huge sets of lab, clinical and patient data, and companies are using artificial intelligence to sort those signals faster than teams of humans can. OpenAI is being brought in at Novo for that data-heavy work, not as a stand-alone lab. (euronews.com) The deal lands as Novo is trying to widen its pipeline beyond current obesity and diabetes blockbusters, including Wegovy and Ozempic. It also comes as Eli Lilly has taken the lead in parts of the obesity market, according to analysts and company results cited by CNBC and Reuters. (cnbc.com) This is also part of a broader Denmark build-out around health care computing. The Novo Nordisk Foundation and Denmark’s Export and Investment Fund launched the Danish Centre for AI Innovation in 2024, and the center’s Gefion system is billed as Denmark’s first artificial-intelligence-ready supercomputer. (novonordiskfonden.dk) Novo already tied into that infrastructure before the OpenAI deal. In June 2025, the Danish Centre for AI Innovation said Novo had become a Gefion customer to process large datasets for drug discovery and health care innovation. (dcai.dk) OpenAI has been moving deeper into pharmaceuticals through partnerships rather than drug programs of its own. In May 2024, Sanofi and Formation Bio said they were working with OpenAI to build software for drug development across the research pipeline. (sanofi.com) For Novo, the immediate test is whether faster analysis turns into faster medicines and steadier production. The company said the aim is to bring new treatments to patients faster, with the first uses starting now across research, factories and commercial teams. (reuters.com)
